Last reviewed · How we verify

Meningococcal vaccine GSK134612 — Competitive Intelligence Brief

Meningococcal vaccine GSK134612 (Meningococcal vaccine GSK134612) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant protein vaccine Neisseria meningitidis serogroup B surface antigens Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Meningococcal vaccine GSK134612 (Meningococcal vaccine GSK134612) — GlaxoSmithKline. This vaccine stimulates the immune system to produce antibodies against meningococcal serogroup B antigens, providing protection against meningococcal disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Meningococcal vaccine GSK134612 TARGET Meningococcal vaccine GSK134612 GlaxoSmithKline phase 3 Recombinant protein vaccine Neisseria meningitidis serogroup B surface antigens
Licensed 4CMenB vaccine Licensed 4CMenB vaccine University of Adelaide marketed Recombinant protein vaccine Neisseria meningitidis serogroup B surface antigens
Meningococcal B Meningococcal B Canadian Immunization Research Network marketed vaccine Neisseria meningitidis serogroup B surface antigens (recombinant proteins)
rMenB+OMV NZ vaccine rMenB+OMV NZ vaccine GlaxoSmithKline marketed Meningococcal serogroup B vaccine Neisseria meningitidis serogroup B surface antigens
Bexsero® vaccine Bexsero® vaccine ANRS, Emerging Infectious Diseases phase 3 Recombinant protein vaccine Neisseria meningitidis serogroup B surface antigens (fHbp, NHBA, NadA, PorA)
MenBvac MenBvac University Hospital, Rouen phase 3 Vaccine Neisseria meningitidis serogroup B surface antigens
Meningococcal B (Bexsero) Meningococcal B (Bexsero) University of Sao Paulo General Hospital marketed Recombinant protein vaccine Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein vaccine class)

  1. GlaxoSmithKline · 6 drugs in this class
  2. Novavax · 5 drugs in this class
  3. Vaxine Pty Ltd · 2 drugs in this class
  4. D'Or Institute for Research and Education · 2 drugs in this class
  5. Protein Sciences Corporation · 2 drugs in this class
  6. Henogen · 1 drug in this class
  7. Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 drug in this class
  8. Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in this class
  9. National Vaccine and Serum Institute, China · 1 drug in this class
  10. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Meningococcal vaccine GSK134612 — Competitive Intelligence Brief. https://druglandscape.com/ci/meningococcal-vaccine-gsk134612. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: